Article Information
History
- February 21, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Faeezah Patel1,*,
- Jean Le Roux1,
- Shobna Sawry1,
- Robert Kieser1,
- Mrinmayee Dhar1,
- Katherine Gill2,
- Erica Lazarus3,
- Anusha Nana3,
- Nigel Garrett4,5,
- Penny L Moore4,6,7,
- Alex Sigal8,9,10,
- Glenda Gray11,
- Helen V Rees1,
- Barry Frank Jacobson12 and
- Lee Fairlie1
- 1Wits RHI, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa
- 2The Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa
- 3Perinatal HIV Research Unit, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- 4Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa
- 5Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa
- 6SA MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa
- 7Center for HIV and STI’s, National Institute of Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa
- 8Africa Health Research Institute, Durban, South Africa
- 9School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa
- 10Max Planck Institute of Infection Biology, Berlin, Germany
- 11HIV and Other Infectious Diseases Research Unit, South Africa Medical Research Council, Cape Town, South Africa
- 12Department of Molecular Medicine and Haematology, University of Witwatersrand, Johannesburg South Africa
- ↵*Corresponding Author: Faeezah Patel, fpatel{at}wrhi.ac.za, +2711 358 5300
Posted February 21, 2024.
Clot Twist – D-dimer analysis of healthy adults receiving heterologous or homologous booster COVID-19 vaccine after a single prime dose of Ad26.COV2.S in a phase II randomised open-label trial, BaSiS
